Cargando…
Anti-Angiogenic Agent Combined with Anti-PD-1 Immunotherapy Showed Activity in Patients With Classical Hodgkin Lymphoma Who Have Failed Immunotherapy: A Retrospective Case Report Study
BACKGROUND: PD-1/PD-L1 inhibitor immunotherapy has showed impressive activity in various cancers, especially relapsed/refractory (r/r) classical Hodgkin lymphoma (cHL). However, acquired resistance is inevitable for most patients. Sometimes severe side effects also lead to treatment termination. Whe...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8664390/ https://www.ncbi.nlm.nih.gov/pubmed/34899689 http://dx.doi.org/10.3389/fimmu.2021.727464 |
_version_ | 1784613836669583360 |
---|---|
author | Yan, Zheng Ma, Jialin Yao, Shuna Yao, Zhihua Wang, Haiying Chu, Junfeng Zhao, Shuang Liu, Yanyan |
author_facet | Yan, Zheng Ma, Jialin Yao, Shuna Yao, Zhihua Wang, Haiying Chu, Junfeng Zhao, Shuang Liu, Yanyan |
author_sort | Yan, Zheng |
collection | PubMed |
description | BACKGROUND: PD-1/PD-L1 inhibitor immunotherapy has showed impressive activity in various cancers, especially relapsed/refractory (r/r) classical Hodgkin lymphoma (cHL). However, acquired resistance is inevitable for most patients. Sometimes severe side effects also lead to treatment termination. When immunotherapy failed, alternative treatment options are limited. In the past few years, we have used the anti-angiogenic agent apatinib and PD-1 inhibitor camrelizumab to treat cHL patients who failed prior immunotherapy. In this study, we analyzed the data of these patients. PATIENTS AND METHODS: Patients with r/r cHL who had failed immunotherapy and subsequently received apatinib-camrelizumab (AC) combination therapy were included in this study. Patient data were collected from medical records and follow-up system. The efficacy and safety of AC therapy were analyzed. RESULTS: Seven patients who failed immunotherapy were identified in our database, of which five patients acquired immunotherapy resistance and two patients experienced severe side effects. They received a combination of camrelizumab (200 mg every four weeks) and apatinib (425 mg or 250 mg per day). As of the cut-off date, these patients had received a median of 4 cycles (range, 2 - 31) of treatment. Two (2/7) patients achieved complete response, four (4/7) partial response, and one (1/7) stable disease. The median progression-free survival was 10.0 months (range, 2.0 – 27.8). Low-dose apatinib (250 mg) plus camrelizumab was well tolerated and had no unexpected side effects. Besides, no reactive cutaneous capillary endothelial proliferation was observed in AC-treated patients. CONCLUSIONS: Low dose apatinib plus camrelizumab might be a promising treatment option for r/r cHL patients who have failed immunotherapy. This combination treatment is worthy of further investigation in more patients including solid cancer patients who have failed immunotherapy. |
format | Online Article Text |
id | pubmed-8664390 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-86643902021-12-11 Anti-Angiogenic Agent Combined with Anti-PD-1 Immunotherapy Showed Activity in Patients With Classical Hodgkin Lymphoma Who Have Failed Immunotherapy: A Retrospective Case Report Study Yan, Zheng Ma, Jialin Yao, Shuna Yao, Zhihua Wang, Haiying Chu, Junfeng Zhao, Shuang Liu, Yanyan Front Immunol Immunology BACKGROUND: PD-1/PD-L1 inhibitor immunotherapy has showed impressive activity in various cancers, especially relapsed/refractory (r/r) classical Hodgkin lymphoma (cHL). However, acquired resistance is inevitable for most patients. Sometimes severe side effects also lead to treatment termination. When immunotherapy failed, alternative treatment options are limited. In the past few years, we have used the anti-angiogenic agent apatinib and PD-1 inhibitor camrelizumab to treat cHL patients who failed prior immunotherapy. In this study, we analyzed the data of these patients. PATIENTS AND METHODS: Patients with r/r cHL who had failed immunotherapy and subsequently received apatinib-camrelizumab (AC) combination therapy were included in this study. Patient data were collected from medical records and follow-up system. The efficacy and safety of AC therapy were analyzed. RESULTS: Seven patients who failed immunotherapy were identified in our database, of which five patients acquired immunotherapy resistance and two patients experienced severe side effects. They received a combination of camrelizumab (200 mg every four weeks) and apatinib (425 mg or 250 mg per day). As of the cut-off date, these patients had received a median of 4 cycles (range, 2 - 31) of treatment. Two (2/7) patients achieved complete response, four (4/7) partial response, and one (1/7) stable disease. The median progression-free survival was 10.0 months (range, 2.0 – 27.8). Low-dose apatinib (250 mg) plus camrelizumab was well tolerated and had no unexpected side effects. Besides, no reactive cutaneous capillary endothelial proliferation was observed in AC-treated patients. CONCLUSIONS: Low dose apatinib plus camrelizumab might be a promising treatment option for r/r cHL patients who have failed immunotherapy. This combination treatment is worthy of further investigation in more patients including solid cancer patients who have failed immunotherapy. Frontiers Media S.A. 2021-11-26 /pmc/articles/PMC8664390/ /pubmed/34899689 http://dx.doi.org/10.3389/fimmu.2021.727464 Text en Copyright © 2021 Yan, Ma, Yao, Yao, Wang, Chu, Zhao and Liu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Yan, Zheng Ma, Jialin Yao, Shuna Yao, Zhihua Wang, Haiying Chu, Junfeng Zhao, Shuang Liu, Yanyan Anti-Angiogenic Agent Combined with Anti-PD-1 Immunotherapy Showed Activity in Patients With Classical Hodgkin Lymphoma Who Have Failed Immunotherapy: A Retrospective Case Report Study |
title | Anti-Angiogenic Agent Combined with Anti-PD-1 Immunotherapy Showed Activity in Patients With Classical Hodgkin Lymphoma Who Have Failed Immunotherapy: A Retrospective Case Report Study |
title_full | Anti-Angiogenic Agent Combined with Anti-PD-1 Immunotherapy Showed Activity in Patients With Classical Hodgkin Lymphoma Who Have Failed Immunotherapy: A Retrospective Case Report Study |
title_fullStr | Anti-Angiogenic Agent Combined with Anti-PD-1 Immunotherapy Showed Activity in Patients With Classical Hodgkin Lymphoma Who Have Failed Immunotherapy: A Retrospective Case Report Study |
title_full_unstemmed | Anti-Angiogenic Agent Combined with Anti-PD-1 Immunotherapy Showed Activity in Patients With Classical Hodgkin Lymphoma Who Have Failed Immunotherapy: A Retrospective Case Report Study |
title_short | Anti-Angiogenic Agent Combined with Anti-PD-1 Immunotherapy Showed Activity in Patients With Classical Hodgkin Lymphoma Who Have Failed Immunotherapy: A Retrospective Case Report Study |
title_sort | anti-angiogenic agent combined with anti-pd-1 immunotherapy showed activity in patients with classical hodgkin lymphoma who have failed immunotherapy: a retrospective case report study |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8664390/ https://www.ncbi.nlm.nih.gov/pubmed/34899689 http://dx.doi.org/10.3389/fimmu.2021.727464 |
work_keys_str_mv | AT yanzheng antiangiogenicagentcombinedwithantipd1immunotherapyshowedactivityinpatientswithclassicalhodgkinlymphomawhohavefailedimmunotherapyaretrospectivecasereportstudy AT majialin antiangiogenicagentcombinedwithantipd1immunotherapyshowedactivityinpatientswithclassicalhodgkinlymphomawhohavefailedimmunotherapyaretrospectivecasereportstudy AT yaoshuna antiangiogenicagentcombinedwithantipd1immunotherapyshowedactivityinpatientswithclassicalhodgkinlymphomawhohavefailedimmunotherapyaretrospectivecasereportstudy AT yaozhihua antiangiogenicagentcombinedwithantipd1immunotherapyshowedactivityinpatientswithclassicalhodgkinlymphomawhohavefailedimmunotherapyaretrospectivecasereportstudy AT wanghaiying antiangiogenicagentcombinedwithantipd1immunotherapyshowedactivityinpatientswithclassicalhodgkinlymphomawhohavefailedimmunotherapyaretrospectivecasereportstudy AT chujunfeng antiangiogenicagentcombinedwithantipd1immunotherapyshowedactivityinpatientswithclassicalhodgkinlymphomawhohavefailedimmunotherapyaretrospectivecasereportstudy AT zhaoshuang antiangiogenicagentcombinedwithantipd1immunotherapyshowedactivityinpatientswithclassicalhodgkinlymphomawhohavefailedimmunotherapyaretrospectivecasereportstudy AT liuyanyan antiangiogenicagentcombinedwithantipd1immunotherapyshowedactivityinpatientswithclassicalhodgkinlymphomawhohavefailedimmunotherapyaretrospectivecasereportstudy |